Skip to main content
Premium Trial:

Request an Annual Quote

Linkage Biosciences Raises $2.1M in Series B Round

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Linkage Biosciences today announced it has raised $2.1 million in a Series B financing round.

The funds will be used to expand manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate molecular tests to market, Zachary Antovich, CEO of Linkage, said in a statement.

Fisher Capital and Greenhouse Capital Partners led the round. All major existing investors, including Big Sky Partners, also were participants.

Linkage raised $2 million in a Series A round in 2009.

Based in San Francisco, Linkage's lead product is its LinkSeq HLA product line, which combines a proprietary software and chemistry platform along with real-time PCR instrumentation to provide "significant improvements in the analysis of complex genetic regions," such as an up-to 85 percent reduction in labor requirements, compared to current methods, Linkage said.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.